Lung Cancer

Joshua Sabari, MD, describes which stage groups of patients with NSCLC should receive neoadjuvant therapies, and which therapies are typically used.

Drs Wakelee, Sabari, and Wistuba review updated data on neoadjuvant treatment in NSCLC from key studies including CheckMate-816 and NADIM-2.

Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.

Dr Bhuvana Ramkumar shares best practices for molecular testing in NSCLC to obtain the most accurate results.

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.

The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.

Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical records, how they address non–small cell lung cancer test results with patients, and their hopes for the future of pathology at their institutions.

Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

Wade T. Iams, MD, discusses the potential for providing small cell lung cancer subtyping in clinical practice.

Vamsidhar Velcheti, MD, summarizes recent data on adjuvant immunotherapy treatment in resectable NSCLC.

Dr Myung-Ju Ahn describes the unique design and outcomes of the NEOCoast study that is evaluating immunotherapy regimens in the neoadjuvant and adjuvant settings.

The panel reviews updates in the treatment of stage I-IIIA NSCLC and discusses its impact in clinical practice.

Ignacio Wistuba, MD, leads the discussion on the role of liquid biopsies for molecular testing in early NSCLC.

What is noteworthy is the process whereby this patient employs both objective data and his personal beliefs to declare what he values.

Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and other solid tumors.

A combination regimen comprised of sotorasib and BBP-398 has been awarded a fast track designation from the FDA for use as a potential therapeutic option in adult patients with previously treated, KRAS G12C–mutated, metastatic non–small cell lung cancer.

The combination of avelumab and axitinib demonstrated promising response rates and progression-free survival and an expected safety profile in pretreated patients with advanced type B3 thymoma and thymic carcinoma, according to findings from an ongoing phase 2 study.

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.

Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.

Mark A. Socinski, MD, has become internationally known for his research into the molecular drivers of lung cancer and his contributions to the refinement of multidisciplinary care.

Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.

Drs Vamsidhar Velcheti and Solange Peters discuss the optimum length for immunotherapy treatment in resectable NSCLC, highlighting the issue of payer authorizations.

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.

The addition of dostarlimab to chemotherapy led to an improvement in objective response rate vs pembrolizumab plus chemotherapy in patients with newly diagnosed metastatic nonsquamous non–small cell lung cancer.

Jonathan Spicer, MD, explains the role of molecular testing in patients with stage I-IIIA NSCLC, and how it informs treatment decision-making.

A panel of lung cancer experts provides an overview of molecular testing in early-stage non-small cell lung cancer (NSCLC) and recommendations for biomarkers to test for and at what treatment stages to perform testing.

The FDA has granted a fast track designation to eftilagimod alpha for use in combination with pembrolizumab as a frontline treatment for patients with stage IIIB/IV non–small cell lung cancer.